Labcorp (LH) Expected to Announce Earnings on Thursday

Key Points

• Labcorp is expected to report Q2 2026 earnings before the market opens on Thursday, July 30, with analysts looking for $4.79 per share on $3.71 billion in revenue.
• The company previously beat expectations in its last quarter, posting $4.25 EPS versus the $4.09 consensus and $3.54 billion in revenue, while revenue rose 5.8% from a year earlier.
• Labcorp recently announced a quarterly dividend of $0.72 per share, and Wall Street remains constructive on the stock with a Moderate Buy consensus and a price target of $314.40.

Labcorp (NYSE:LH - Get Free Report) will likely be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $4.79 per share and revenue of $3.7094 billion for the quarter. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Individuals are encouraged to explore the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 9:00 AM ET.

Labcorp (NYSE:LH - Get Free Report) last announced its earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping the consensus estimate of $4.09 by $0.16. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. Labcorp's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.84 EPS. On average, analysts expect Labcorp to post $18 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Labcorp Stock Up 0.9%

Labcorp stock opened at $281.85 on Thursday. The company's 50-day moving average price is $267.72 and its two-hundred day moving average price is $268.63. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The stock has a market cap of $23.11 billion, a P/E ratio of 24.96, a P/E/G ratio of 1.85 and a beta of 0.89. Labcorp has a twelve month low of $244.52 and a twelve month high of $293.72.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp's dividend payout ratio is presently 25.51%.

Insider Activity at Labcorp

In other Labcorp news, EVP Kathryn W. Kyle sold 762 shares of the business's stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $263.89, for a total transaction of $201,084.18. Following the completion of the transaction, the executive vice president owned 3,813 shares of the company's stock, valued at approximately $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the transaction, the executive vice president owned 6,746 shares of the company's stock, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 6,991 shares of company stock valued at $1,796,696 over the last three months. 0.84% of the stock is owned by insiders.

Hedge Funds Weigh In On Labcorp

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in Labcorp by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company's stock worth $604,488,000 after acquiring an additional 289,029 shares during the last quarter. Marshall Wace LLP grew its position in shares of Labcorp by 79.1% in the 3rd quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company's stock valued at $178,996,000 after buying an additional 275,454 shares during the last quarter. Millennium Management LLC increased its stake in shares of Labcorp by 2,491.3% in the fourth quarter. Millennium Management LLC now owns 277,323 shares of the medical research company's stock valued at $69,575,000 after buying an additional 266,621 shares during the period. Woodline Partners LP increased its stake in shares of Labcorp by 598.1% in the third quarter. Woodline Partners LP now owns 287,146 shares of the medical research company's stock valued at $82,428,000 after buying an additional 246,014 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Labcorp by 19.8% during the fourth quarter. JPMorgan Chase & Co. now owns 1,287,177 shares of the medical research company's stock worth $322,927,000 after acquiring an additional 213,136 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LH shares. Bank of America increased their target price on Labcorp from $300.00 to $320.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Robert W. Baird boosted their price target on Labcorp from $335.00 to $338.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Wall Street Zen raised Labcorp from a "hold" rating to a "buy" rating in a report on Sunday, July 12th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Labcorp in a research report on Friday, May 8th. Finally, Evercore reissued an "outperform" rating and set a $300.00 target price on shares of Labcorp in a report on Wednesday, April 8th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Labcorp presently has a consensus rating of "Moderate Buy" and a consensus price target of $314.40.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.